Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 7.5% – Here’s Why

Structure Therapeutics Inc. (NASDAQ:GPCR) shares were up 7.5% during trading on Wednesday . The company traded as high as $17.16 and last traded at $16.97. Approximately 584,887 shares traded hands during mid-day trading, a decline of 31% from the average daily volume of 850,763 shares. The stock had previously closed at $15.79.

Analysts Set New Price Targets

A number of brokerages recently weighed in on GPCR. Stifel Nicolaus assumed coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. Finally, William Blair started coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They issued an “outperform” rating for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics has an average rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Stock Performance

The company has a market capitalization of $981.14 million, a PE ratio of -23.12 and a beta of -2.37. The company’s 50-day moving average is $23.74 and its 200 day moving average is $30.82.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. On average, analysts forecast that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of GPCR. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Structure Therapeutics in the fourth quarter worth approximately $3,091,000. GF Fund Management CO. LTD. purchased a new position in Structure Therapeutics in the 4th quarter worth approximately $34,000. Woodline Partners LP lifted its holdings in shares of Structure Therapeutics by 0.7% in the fourth quarter. Woodline Partners LP now owns 333,901 shares of the company’s stock worth $9,055,000 after buying an additional 2,328 shares in the last quarter. Vestal Point Capital LP boosted its holdings in shares of Structure Therapeutics by 50.0% during the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $46,782,000 after purchasing an additional 575,000 shares during the last quarter. Finally, Twinbeech Capital LP grew its holdings in shares of Structure Therapeutics by 34.3% in the fourth quarter. Twinbeech Capital LP now owns 28,268 shares of the company’s stock valued at $767,000 after purchasing an additional 7,220 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.